TY - JOUR
T1 - Locally advanced cervical cancer with bladder invasion
T2 - Clinical outcomes and predictive factors for vesicovaginal fistulae
AU - Sun, Roger
AU - Koubaa, Ines
AU - Limkin, Elaine Johanna
AU - Dumas, Isabelle
AU - Bentivegna, Enrica
AU - Castanon, Eduardo
AU - Gouy, Sébastien
AU - Baratiny, Cynthia
AU - Monnot, Fyo
AU - Maroun, Pierre
AU - Ammari, Samy
AU - Zareski, Elise
AU - Balleyguier, Corinne
AU - Deutsch, Éric
AU - Morice, Philippe
AU - Haie-Meder, Christine
AU - Chargari, Cyrus
N1 - Publisher Copyright:
© Sun et al.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Objective: We report outcomes of cervical cancer patients with bladder invasion (CCBI) at diagnosis, with focus on the incidence and predictive factors of vesicovaginal fistula (VVF). Results: Seventy-one patients were identified. Twenty-one (30%) had paraaortic nodal involvement. Eight had VVF at diagnosis. With a mean follow-up time of 34.2 months (range: 1.9 months-14.8 years), among 63 patients without VVF at diagnosis, 15 (24%) developed VVF. A VVF occurred in 19% of patients without local relapses (9/48) and 40% of patients with local relapse (6/15). Two-year overall survival (OS), disease-free survival (DFS) and local control rates were 56.4% (95% CI: 44.1-67.9%), 39.1% (95% CI: 28.1-51.4%) and 63.8% (95% CI: 50.4-75.4%), respectively. Para-aortic nodes were associated with poorer OS (adjusted HR = 3.78, P-value = 0.001). In multivariate analysis, anterior tumor necrosis on baseline MRI was associated with VVF formation (63% vs 0% at 1 year, adjusted-HR = 34.13, 95% CI: 4.07-286, P-value = 0.001), as well as the height of the bladder wall involvement of > 26 mm (adjusted-HR = 5.08, 95% CI: 1.38-18.64, P-value = 0.014). Conclusions: A curative intent strategy including brachytherapy is feasible in patients with CCBI, with VVF occurrence in 24% of the patients. MRI patterns help predicting VVF occurrence. Methods: Patients with locally advanced CCBI treated with (chemo)radiation ± brachytherapy in our institute from 1989 to 2015 were analyzed. Reviews of baseline magnetic resonance imaging (MRI) scans were carried out blind to clinical data, retrieving potential parameters correlated to VVF formation (including necrosis and tumor volume).
AB - Objective: We report outcomes of cervical cancer patients with bladder invasion (CCBI) at diagnosis, with focus on the incidence and predictive factors of vesicovaginal fistula (VVF). Results: Seventy-one patients were identified. Twenty-one (30%) had paraaortic nodal involvement. Eight had VVF at diagnosis. With a mean follow-up time of 34.2 months (range: 1.9 months-14.8 years), among 63 patients without VVF at diagnosis, 15 (24%) developed VVF. A VVF occurred in 19% of patients without local relapses (9/48) and 40% of patients with local relapse (6/15). Two-year overall survival (OS), disease-free survival (DFS) and local control rates were 56.4% (95% CI: 44.1-67.9%), 39.1% (95% CI: 28.1-51.4%) and 63.8% (95% CI: 50.4-75.4%), respectively. Para-aortic nodes were associated with poorer OS (adjusted HR = 3.78, P-value = 0.001). In multivariate analysis, anterior tumor necrosis on baseline MRI was associated with VVF formation (63% vs 0% at 1 year, adjusted-HR = 34.13, 95% CI: 4.07-286, P-value = 0.001), as well as the height of the bladder wall involvement of > 26 mm (adjusted-HR = 5.08, 95% CI: 1.38-18.64, P-value = 0.014). Conclusions: A curative intent strategy including brachytherapy is feasible in patients with CCBI, with VVF occurrence in 24% of the patients. MRI patterns help predicting VVF occurrence. Methods: Patients with locally advanced CCBI treated with (chemo)radiation ± brachytherapy in our institute from 1989 to 2015 were analyzed. Reviews of baseline magnetic resonance imaging (MRI) scans were carried out blind to clinical data, retrieving potential parameters correlated to VVF formation (including necrosis and tumor volume).
KW - Bladder invasion
KW - Brachytherapy
KW - Cervical cancer
KW - Locally advanced
KW - Vesicovaginal fistula
UR - http://www.scopus.com/inward/record.url?scp=85041399957&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.24271
DO - 10.18632/oncotarget.24271
M3 - Article
C2 - 29507691
AN - SCOPUS:85041399957
SN - 1949-2553
VL - 9
SP - 9299
EP - 9310
JO - Oncotarget
JF - Oncotarget
IS - 10
ER -